The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
Status:
Completed
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
Diabetic nephropathy (DN) is one of the most frequent microvascular complications of diabetes
mellitus, affecting 25 to 40% of patients with type 1 diabetes (T1DM). Early diagnosis,
appropriate patient follow-up and treatment are essential to improve the outcomes. There is a
need for improvements in insulin therapy for people with T1DM as the majority of patients are
struggling to achieve glycemic targets. Technological advancements and oral adjuncts to
insulin therapies are starting to be licensed for the use of people with T1DM.
Dipeptidyl peptidase-4 (DPP-4), a multifunctional serine protease with a dual function
(regulatory protease and binding protein), can modulate inflammation and immune cell-mediated
β-cell destruction. DPP-4 degrades the peptide hormones glucagon-like peptide 1 (GLP-1) and
gastric inhibitory peptide (GIP). Several studies have suggested that the upregulated DPP-4
activity is correlated with T1DM pathophysiology.